Results 131 to 140 of about 49,111 (247)

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus   +7 more
wiley   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

open access: yesInternational Journal of Cancer, Volume 159, Issue 9, Page 2244-2261, 1 November 2026.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko   +31 more
wiley   +1 more source

THE JOURNAL Canine-Effective Plasma Concentrations of Antiarrhythmic Drugs on the Two-Stage Coronary Ligation Arrhythmia1

open access: yes, 2020
Seven drugs were tested for their antiarrhythmic effects on 6.4 tg/ml; and a new beta ...
Hiroyasu Satoh   +4 more
core  

Ventricular IKur: The unwelcome guest

open access: yes
The Journal of Physiology, EarlyView.
Antonio Zaza, Claudia Maniezzi
wiley   +1 more source

Curcumin in the Treatment of Various Diseases: Mechanism of Action, Bioavailability, Therapeutic Effects, and Current Clinical Trials

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Curcumin, a naturally occurring polyphenol, exhibits significant anti‐inflammatory and antioxidant capabilities. This review elucidates the specific molecular mechanisms by which curcumin exerts therapeutic effects on various diseases, including neurological disorders, cardiovascular diseases, cancers, inflammatory disorders, and autoimmune diseases ...
Lin Wang   +15 more
wiley   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1477-1498, November 2026.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood   +7 more
wiley   +1 more source

Essential antiarrhythmic drug accessibility worldwide: a multi-survey study and comprehensive evaluation of access and supply challenges. [PDF]

open access: yesEuropace
Postema PG   +15 more
europepmc   +1 more source

Late INa as a Therapeutic Target: New Strategies, Computational Modelling, Drug Development, and Clinical Translation

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1939-1957, November 2026.
ABSTRACT The Nav1.5 channel, a major isoform of voltage‐gated sodium ion channel, is mainly found in ventricular cardiomyocytes, playing a key role in generating essential cardiac action potentials for normal heart rhythms. Mutations in Nav1.5 have been associated with severe heart conditions such as long QT syndrome, Brugada syndrome, cardiac ...
Arkapravo Chattopadhyay   +3 more
wiley   +1 more source

Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents. [PDF]

open access: yesCurr Cardiol Rep
Palermi A   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy